The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
A direct comparison between liraglutide and exenatide is the best way to show liraglutide's true benefit as a GLP-1 analogue. Novo Nordisk did just that and the results bode well for liraglutide. Once daily liraglutide will soon replace exenatide, given its equivalent efficacy in reducing HbA1c and...
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b,...
There have been great advances made over the past 40 years in cardiovascular risk assessment. Nevertheless, 600 people die each day of sudden death. The majority of these individuals had conditions that could have been treated and corrected.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Study will be ridiculed. 1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
Copaxone has become the leading treatment for relapsing remitting MS in the US. The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.
Merck continues to have problems as a result of Vioxx. It recently came out that the research studies which had been allegedly authored by independent medical scientists were actually ghostwritten by individuals paid by Merck. Many physicians have a poor opinion of industry sponsored research...
As a partner @ a VC fund I see this trend impacting how potential portfolio companies are evaluated. Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded. Investment decisons are also being influenced by the potential...
The potential side effect of liver damage of the new cholesterol agent from Merck will definitely slow or even halt the FDA approval of the medication.